Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- AbbVie
- Study ID
- NCT03951077
- Phase
- PHASE2
- Status
- Completed
Conditions
- Polycystic Ovary Syndrome
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - 35 Years
- Healthy Volunteers
- Not accepted
Interventions
- Elagolix — DRUGCapsule administered orally
- Placebo — DRUGCapsule administered orally
Study Details
This study will assess the potential impact of elagolix on disordered pituitary and ovarian hormones in women with polycystic ovary syndrome (PCOS).
Key Dates
- Start date
- Aug 12, 2019
- Status verified
- May 2022
- Primary completion
- Feb 10, 2021
- Completion
- Feb 10, 2021
Study Design
- Enrollment
- 118 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Placebo Comparator: PlaceboPlacebo taken orally twice a day (BID)
- Experimental: Elagolix 25 mg BIDElagolix 25 mg taken orally BID plus placebo
- Experimental: Elagolix 50 mg Once Daily (QD)Elagolix 50 mg taken orally QD plus placebo
- Experimental: Elagolix 75 mg BIDElagolix 75 mg taken orally BID plus placebo
- Experimental: Elagolix 150 mg QDElagolix 150 mg taken orally QD plus placebo
- Experimental: Elagolix 300 mg QDElagolix 300 mg taken orally QD plus placebo
Primary Outcome Measure
Percentage of Menstrual Cycle Responders [ Time Frame: Week 0 (Baseline) to Week 24 (Month 6) ]
Locations (50)
Find similar trials in Birmingham, AL
Related Studies
- The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor AgonistsPHASE1 · Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- IVM With Low Cost Priming, Enhanced Oocyte Recovery, and Delayed TransferRecruiting · Bruce Rose, MD · Jacksonville, Florida
- Apple Women's Health StudyRecruiting · Apple Inc. · Boston, Massachusetts
- The PCOS Challenge StudyRecruiting · PCOS Challenge: The National Polycystic Ovary Syndrome Association · Bethesda, Maryland